This report analyses the financial performance of Dr.Max for the 2018. You will find all the necessary details regarding company's profitability, volume growth, indebtedness and a comparison with selected peers.
Dr.Max announced a net profit of CZK 108 mil in 2018, down 18.2% when compared to the last year. Sales increased 11.4% yoy to CZK 17,949 mil, EBITDA rose 3.23% to CZK 921 mil and net margin amounted to 0.603%. In the last three years, the Company grew its revenues by 8.24% a year, and produced an average return on capital of 1.56% and return on equity of 9.11%.
The key highlights are:
Sales increased 11.4% yoy to CZK 17,949 mil in 2018. That’s compared to average growth of 8.24% in the last three years and 22.3% more when compared to the average annual increase in the last decade.
EBITDA amounted to CZK 921 mil and grew 3.23% when compared to last year. EBITDA margin reached 5.13%, up 0.508%pp when compared to a 5-year average.
Company’s indebtedness fell when measured by Net Debt/Equity and reached 159% at the end of 2018. When compared to EBITDA, net debt fell to 6.44x at the end of 2018.
Dr.Max netted CZK 108 mil to its shareholders in the last year, down 51.7% when compared to the average seen in the last five years. The company produced a return on capital of 1.06% and return on equity of 3.85% in the last year. Since 2013, Dr.Max’s average ROCE amounted to 2.07% and ROE 5.23%.
When compared to selected peers, Dr.Max has grown 2.52 pp faster in sales in the last five years. It was also 6.08 pp less profitable in terms of ROCE, and achieved 0.252 pp higher EBITDA margin based on a last year's results.
In terms of indebtedness, the company operated with 51.2 pp higher net debt to equity at the end of 2018 when compared to its peers (159% at Dr.Max vs. 107% of its peers).
Helgi Library 
